Saturday 17 October 2026 Export XRAY’s income statement to Excel — free account

DENTSPLY SIRONA Inc.

XRAY Healthcare Medical Instruments & Supplies

DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue fell 4.06%, EPS grew 181.8%, free cash flow grew 252.9% and total debt fell 10.0%, each against the same quarter a year earlier. Dividend growth for twenty-five consecutive years; insiders bought in the last twelve months.

8.57 0.26 −2.94%

Follow XRAY

Alert me

Market cap: $1.8B
P/E: 0.0×
Fwd P/E: 27.0×
Dividend yield: 1.87%
F-score: 6/9
Altman Z: 0.50
Beneish M: −3.03
Dividend safety: 22/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.74

Total sells 0.92

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	4	—	—	6	—	—	—	—
Sell	—	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.02%

Capital & Financial Ratios $m

Market Cap 1,760.00

Revenue 3,643.00

Net Income (547.00)

Free Cash Flow 147.00

Net Debt 1,757.00

Current Ratio 1.63

Debt/Equity 1.48

P/E ratio 0.00

Fwd P/E 27.00

P/S ratio 0.47

P/B ratio 1.27

Past 5Y EPS Growth —

This Y EPS Growth (4.40%)

Next Y EPS Growth (2.12%)

Next Y revenue growth (2.96%)

Next 5Y EPS Growth 0.80%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.26%

10-year low 10-year high

P/B against its own 10 years 1.33%

10-year low 10-year high

EV/Sales against its own 10 years 0.26%

10-year low 10-year high

EV/FCF against its own 10 years 31.11%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.16

Annual Dividend Yield 1.87%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	Powerpack
2025	0.64	0.16 0.16 0.16 0.16
2024	0.64	0.16 0.16 0.16 0.16
2023	0.56	0.14 0.14 0.14 0.14
2022	0.50	0.13 0.13 0.13 0.13
2021	0.43	0.10 0.11 0.11 0.11
2020	0.40	0.10 0.10 0.10 0.10
2019	0.38	0.09 0.09 0.10 0.10
2018	0.35	0.09 0.09 0.09 0.09
2017	0.44	0.09 0.09 0.09 0.09 0.09
2016	0.31	0.08 0.08 0.08 0.08

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	334	272	326	239
Receivables	695	556	688	620
Inventory	624	564	642	665
Other	—	—	—	—
	1,973	1,746	2,023	1,928

	2023	2024	2025	Q'26
Payables	305	241	300	260
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1,425	1,589	1,343	1,185

Compound Annual Growth %

	10y	5y	3y
Sales	3.24%	1.96%	(2.10%)
Cash Flow	(7.22%)	(18.39%)	(23.11%)
Earnings	0.00%	0.00%	0.00%
Book Value	(5.42%)	(22.95%)	(29.43%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	880	898	—	—	—
’25	879	936	904	961	3,680
’24	953	984	951	905	3,793
’23	978	1,028	947	1,012	3,965
’22	969	1,023	947	983	3,922
’21	1,026	1,062	1,040	1,103	4,231
’20	874	491	883	1,091	3,339

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	40	99	—	—	—
’25	7	48	79	101	235
’24	25	208	141	87	461
’23	(21)	104	134	160	377
’22	93	173	109	142	517
’21	49	214	172	222	657
’20	(10)	174	221	264	649

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	60	—	—	—
’25	(12)	17	39	60	104
’24	(9)	157	97	36	281
’23	(60)	71	97	120	228
’22	49	132	77	110	368
’21	19	179	136	181	515
’20	(35)	161	199	237	562

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.05)	0.18	—	—	—
’25	0.10	(0.22)	(2.14)	(0.74)	(3.00)
’24	0.09	(0.02)	(2.46)	(2.16)	(4.48)
’23	(0.09)	0.40	(1.25)	0.32	(0.62)
’22	0.30	0.34	(5.01)	(0.07)	(4.41)
’21	0.53	0.45	0.47	0.47	1.91
’20	(0.63)	(0.44)	0.25	0.45	(0.38)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	53.43	52.54	33.93	36.63	31.58	48.13	26.48	26.27	17.21	9.85	Analyst estimates 2026–2028 Powerpack
	High	65.83	68.98	68.47	60.15	60.87	69.54	58.70	43.24	37.60	20.60
People
People	Employees	15,700	16,100	16,400	15,200	15,000	15,000	15,000	15,000	14,000	14,000
	Revenue/emp, $m	0.24	0.25	0.24	0.26	0.22	0.28	0.26	0.26	0.27	0.26
Income, $m
Income, $m	Revenue	3,745	3,993	3,986	4,022	3,339	4,231	3,922	3,965	3,793	3,680
	Gross margin, %	53.42	54.80	51.88	53.80	49.60	55.47	54.23	52.61	51.62	50.00
	EBT	441	(1,603)	(958)	338	(50)	545	(1,055)	(175)	(936)	(486)
	EBT margin, %	11.77	(40.15)	(24.03)	8.40	(1.50)	12.88	(26.90)	(4.41)	(24.68)	(13.21)
	Net income	431	(1,550)	(1,011)	256	(73)	411	(950)	(132)	(910)	(598)
	Depreciation	276	1,970	1,420	323	491	346	1,515	634	1,122	877
Per share, $
Per share, $	Revenue	17.18	17.41	17.77	18.03	15.23	19.37	18.20	18.70	18.67	18.46
	Earnings	1.97	(6.86)	(4.51)	1.18	(0.38)	1.93	(4.41)	(0.62)	(4.48)	(3.00)
	Cash flow	2.58	2.62	2.23	2.86	2.96	3.01	2.40	1.78	2.27	1.18
	Capex	(0.56)	(0.63)	(0.80)	(0.55)	(0.40)	(0.65)	(0.69)	(0.70)	(0.89)	(0.66)
	Free cash flow	2.03	2.00	1.43	2.31	2.56	2.36	1.71	1.08	1.38	0.52
	Book value	37.27	28.89	22.88	22.84	22.51	22.88	17.69	15.54	9.56	6.72
	Shares, m	218	229	224	223	219	218	216	212	203	199
Valuation, ×
Valuation, ×	P/E	28.88	0.00	0.00	47.96	0.00	29.06	0.00	0.00	0.00	0.00
	P/S	3.41	3.86	2.09	3.14	3.44	2.88	1.80	1.91	1.02	0.62
	P/B	1.57	2.32	1.63	2.48	2.33	2.44	1.85	2.29	1.98	1.70
	EV/Sales	3.71	4.18	2.41	3.39	3.90	3.25	2.17	2.27	1.36	1.08
	EV/FCF	31.81	36.42	29.91	26.72	23.37	26.98	23.43	40.43	18.73	40.08
Cash, $m
Cash, $m	Operating cash flow	563	602	500	639	649	657	517	377	461	235
	Capex	(121)	(144)	(179)	(123)	(87)	(142)	(149)	(149)	(180)	(131)
	Free cash flow	442	458	321	516	562	515	368	228	281	104
Balance, $m
Balance, $m	Working capital	976	1,048	875	1,005	426	591	723	548	157	680
	Total debt	1,511	1,612	1,565	1,433	1,978	1,913	1,826	1,796	1,586	2,015
	Net debt	1,127	1,291	1,255	1,028	1,540	1,574	1,461	1,462	1,314	1,689
	Shareholders’ equity	8,126	6,628	5,133	5,095	4,935	4,997	3,812	3,294	1,943	1,340
Returns, %
Returns, %	ROA	5.39	(14.14)	(10.61)	2.96	(0.81)	4.42	(11.25)	(1.76)	(13.87)	(10.70)
	ROIC	3.07	(12.33)	(9.37)	3.60	(0.03)	5.78	(11.11)	(1.12)	(16.87)	(8.71)
	ROE	8.22	(21.01)	(17.19)	5.01	(1.46)	8.28	(21.57)	(3.72)	(34.75)	(36.43)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NVST Envista Holdings Corporation	$3.8B	38.8×	24.4×	+7.10% (above 0%: growing)	+106.25% (above 0%: growing)	+37.57% (above 0%: growing)	55.72%	10.99%	Compare
PLSE Pulse Biosciences, Inc	$3.3B	— (loss-making)	— (loss-making)	+4,922.22% (above 0%: growing)	n/m	−45.39% (below 0%: shrinking)	37.10%	(5,823.04%)	Compare
WRBY Warby Parker Inc.	$3.0B	334×	122×	+9.81% (above 0%: growing)	n/m	−71.75% (below 0%: shrinking)	57.94%	1.34%	Compare
ATRC AtriCure, Inc.	$2.9B	259×	591×	+12.83% (above 0%: growing)	n/m	−2.79% (below 0%: shrinking)	77.23%	6.29%	Compare
LMAT LeMaitre Vascular, Inc.	$1.9B	27.9×	31.5×	+9.57% (above 0%: growing)	+22.95% (above 0%: growing)	−27.95% (below 0%: shrinking)	72.13%	28.98%	Compare
XRAY DENTSPLY SIRONA Inc.	$1.8B	— (loss-making)	27.0×	−4.06% (below 0%: shrinking)	n/m	+252.94% (above 0%: growing)	54.90%	9.13%
KMTS Kestra Medical Technologies, Ltd.	$1.7B	— (loss-making)	— (loss-making)	+59.88% (above 0%: growing)	n/m	−17.75% (below 0%: shrinking)	56.50%	(121.59%)	Compare
AZTA Azenta, Inc.	$1.6B	— (loss-making)	— (loss-making)	+12.04% (above 0%: growing)	n/m	−134.69% (below 0%: shrinking)	44.89%	(2.59%)	Compare
STAA STAAR Surgical Company	$1.1B	304×	103×	+111.04% (above 0%: growing)	n/m	+166.10% (above 0%: growing)	74.55%	10.80%	Compare
Median of peers	$2.4B	259×	103×	+12.43%	—	−22.85%	57.22%	3.81%

All 55 Medical Instruments & Supplies stocks →

DENTSPLY SIRONA Inc. (XRAY) key facts

Concern: DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024.
Concern: DENTSPLY SIRONA Inc. reported a net loss of $598.0 million, or a loss of $3.00 per share, for fiscal 2025.
DENTSPLY SIRONA Inc. (XRAY) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, XRAY traded at $8.57, a market capitalization of $1.8 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.5× sales.
DENTSPLY SIRONA Inc. pays an annual dividend of $0.16 per share, a yield of 1.87%.
Return on equity was −36.4% and debt-to-equity 1.48.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 0.50 (distress zone) for fiscal 2025.